A 52-week randomized,double-blind, placebocontrolled, multi-center Phase 2b study with a 52-week blinded extension assessing safety and efficacy of frexalimab, a CD40L antagonist monoclonal antibody, for preservation of pancreatic ß-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy

• Código protocolo: DRI17476
• Código EudraCT: No aplica
• Grupo de investigación: Diabetes y Metabolismo
• Servicio: Endocrinología
• Investigador/a principal:  Hernández Pascual, Cristina
• Patología: Malalties endocrines, nutricionals i metabòliques
• Fase: Fase II